People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Other Technology, Biotechnology, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DiCE MOLECULES HOLDINGS, LLC | — | Other Technology | Series C | $158.8M | $1.3B | 2020 |
| 4D Molecular Therapeutics Inc | — | Biotechnology | Series C | $108.6M | $3.7B | 2015 |
| Siren Biotechnology, Inc. | — | Biotech | Series B | $19.6M | $154.4M | 2024 |
| Cessation Therapeutics, Inc. | — | Biotechnology | Series A | $6.8M | $5.9M | 2024 |
Sharon Tetlow at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sharon Tetlow on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Rubin | 1 | 8 |
| Jake Simson | 1 | 6 |
| Shaan Gandhi | 1 | 4 |
| Richard Scheller | 1 | 4 |
| David Genecov | 1 | 4 |
| Tony Yao | 1 | 3 |
| Jay Shepard | 1 | 3 |
| Scott Robertson | 1 | 3 |
| John Harkey | 1 | 3 |
| John Bedbrook | 1 | 3 |
| Brad Allen | 1 | 3 |
| Kevin Judice | 1 | 3 |
| Daniel Fine | 1 | 3 |
| Stephen Zachary | 1 | 2 |
| David Kirn | 1 | 2 |
| Michael Rabson | 1 | 2 |
| Margi McLoughlin | 1 | 2 |
| Eric Rasmussen | 1 | 2 |
| Jim Scopa | 1 | 2 |
| Pehr Harbury | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.